Pharma players see faster growth in China amid medical reforms
Several drug makers are expecting more mergers and acquisitions in China's pharmaceutical sector, which is undergoing a nationwide reform, the Hong Kong Economic Journal reported Monday.
Medical reforms in mainland China will change the ecosystem of the sector and provide more opportunities to small biotechnology and pharmaceutical companies, said Li Xiaoyi, founder and chief executive of Lee's Pharmaceutical Holdings Ltd. (00950.HK).
More mergers and acquisitions are likely, Li said.
Lee's Pharmaceutical has long relied on organic growth while paying close attention to potential acquisitions, he said.
Innovent Biologic Inc. chairman Yu Dechao, meanwhile, expects more opportunities to arise in biopharmaceutical development, which aims to provide the mainland market with more affordable biopharmaceutical medicines.
China lags way behind in this area, Yu said.
He said antibiotics make up only 2 percent of sales of drugs in mainland China, as compared with 40 percent globally.
Nonetheless, this is a segment with an extremely high entry barrier, because of the colossal size of development funds involved, which could be up to US$2 bilion for a drug.
Lack of high-caliber professionals is another issue that has to be resolved, Yu said.
Meanwhile, Bright Future Pharmaceutical Laboratories Ltd. managing director Chan Chak-yeung said the company will continue to locate its manufacturing base in Hong Kong, which has an environment of fair competition and a good pool of talent.
Chan said Hong Kong is a good place from which to supply high-end drugs to the mainland market.
-- Contact us at [email protected]
VW/JP/FL
-
Financial chief earmarks HK$934 million to boost tourism
Apart from handing out HK$5,000 spending e-coupons to Hongkongers to stimulate local spending, the revival of tourism, also hard hit by the Covid-19 pandemic, is another key issue financial chief
-
When are we going to get our HK$5,000 e-vouchers?
Among the economic stimulus measures financial chief Paul Chan revealed yesterday in the 2021-22 budget, the disbursement of HK$5,000 spending e-vouchers is probably what the public is most
-
Carrie Lam is Hong Kong’s biggest failure, not RTHK Michael Chugani
Normally I would focus on Financial Secretary Paul Chan Mo-po's budget whichhe unveiled yesterday. Not this year, except to say he tried his best with an austerity budget that still offered HK$5,000
-
Getting a jab: One step closer to Covid travel visa Ben Kwok
Whether Hong Kong people would take the vaccine shot from Sinovac or BioNTech is less of a question than when they can fly to where they want with the vaccine passport. In the first place, who wants
-
New levy and more RVMs to boost waste recycling efforts
To move toward the city’s long term waste reduction goal, the government is proposing a recycling levy on makers and importers of plastic beverage bottles. At the same time, the government is also
